NCT03786081 2026-03-13Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical CancerSeagen Inc.Phase 1/2 Active not recruiting214 enrolled
NCT05866354 2023-11-27To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid MalignanciesZai Lab (Hong Kong), Ltd.Phase 1 Completed19 enrolled
NCT03438396 2023-07-25A Trial of Tisotumab Vedotin in Cervical CancerSeagen Inc.Phase 2 Completed102 enrolled 20 charts 1 FDA
NCT02001623 2021-12-29Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid TumorsSeagen Inc.Phase 1/2 Completed195 enrolled 51 charts
NCT03245736 2021-11-04Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.Seagen Inc.Phase 2 Completed5 enrolled 8 charts
NCT02552121 2021-04-08Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid TumorsSeagen Inc.Phase 1/2 Completed33 enrolled 70 charts